Since SITC published its first CPG for the use of immunotherapy for the treatment of bladder carcinoma in 2017, immunotherapeutic options for the treatment of urothelial cancer have expanded substantially with approvals for checkpoint inhibitors in multiple advanced disease settings and emerging data on adjuvant approaches.
SITC's Urothelial Cancer Immunotherapy Guideline Expert Panel convened to developed and publish an updated CPG, "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment or urothelial cancer" on July 15, 2021 in the Journal for Immunotherapy of Cancer (JITC) to help clinicians navigate the evolving therapeutic landscape and ultimately improve outcomes for patients, SITC's panel of experts generated updated and expanded evidence- and consensus-based recommendations on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs) and patient quality of life (QOL) considerations.SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced.
Published July 15, 2021 in the Journal for ImmunoTherapy of Cancer (JITC) as "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer"
In this introductory webinar, Expert Panel members provide attendees with an overview of the published guideline and highlight selected recommendations that are applicable to some of the most commonscenarios clinicians may encounter while treating their patients with immunotherapy. After attending this webinar, learners will be better able to implement immunotherapy treatments effectively and in accordance with the recommendations in the SITC CPG.CME, CNE and CPE credits are available for live attendees.
This advanced webinar is designed so that attendees will know how to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease. This webinar is not accredited.
Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
Arjun V. Balar, MD — Perlmutter Cancer Center - New York University Langone Medical Center
Peter Black, MD, FACS, FRCSC — The University of British Columbia
Matthew T. Campbell, MD, MS — The University of Texas MD Anderson Cancer Center
Gail S. Dykstra, Patient Research Advocate — Bladder Cancer Advocacy Network (BCAN); Dykstra Research
Petros Grivas, MD, PhD — University of Washington
Shilpa Gupta, MD — Cleveland Clinic Taussig Cancer Institute
Christopher J. Hoimes, MD — Duke Cancer Institute
Lidia P. Lopez, APN-C — The University of California Los Angeles
Joshua J. Meeks, MD, PhD — Northwestern Medicine Feinberg School of Medicine
Elizabeth R. Plimack, MD, MS — Fox Chase Cancer Center
Jonathan E. Rosenberg, MD — Memorial Sloan Kettering Cancer Center
Neil Shore, MD, FACS — Carolina Urologic Research Center
Gary D. Steinberg, MD — Perlmutter Cancer Center - New York University Langonge Medical Center
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org